SG71173A1 - 1,3,8,-triaza-spiro[4,5]decan-4-on derivatives - Google Patents

1,3,8,-triaza-spiro[4,5]decan-4-on derivatives

Info

Publication number
SG71173A1
SG71173A1 SG1998005141A SG1998005141A SG71173A1 SG 71173 A1 SG71173 A1 SG 71173A1 SG 1998005141 A SG1998005141 A SG 1998005141A SG 1998005141 A SG1998005141 A SG 1998005141A SG 71173 A1 SG71173 A1 SG 71173A1
Authority
SG
Singapore
Prior art keywords
triaza
decan
spiro
derivatives
Prior art date
Application number
SG1998005141A
Other languages
English (en)
Inventor
Geo Adam
Andrea Cesure
Guido Galley
Francois Jenck
Stephan Roever
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG71173A1 publication Critical patent/SG71173A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Color Printing (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
SG1998005141A 1997-12-05 1998-12-03 1,3,8,-triaza-spiro[4,5]decan-4-on derivatives SG71173A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97121427 1997-12-05

Publications (1)

Publication Number Publication Date
SG71173A1 true SG71173A1 (en) 2000-03-21

Family

ID=8227753

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1998005141A SG71173A1 (en) 1997-12-05 1998-12-03 1,3,8,-triaza-spiro[4,5]decan-4-on derivatives

Country Status (29)

Country Link
US (1) US6043366A (da)
JP (1) JP3366868B2 (da)
KR (1) KR19990062800A (da)
CN (1) CN1118467C (da)
AR (1) AR016428A1 (da)
AT (1) ATE212635T1 (da)
AU (1) AU744338B2 (da)
BR (1) BR9805297B1 (da)
CA (1) CA2255171C (da)
CO (1) CO4990965A1 (da)
CZ (1) CZ399698A3 (da)
DE (1) DE69803653T2 (da)
DK (1) DK0921125T3 (da)
ES (1) ES2170446T3 (da)
HR (1) HRP980613A2 (da)
HU (1) HUP9802807A3 (da)
ID (1) ID21413A (da)
IL (1) IL127399A0 (da)
MA (1) MA26573A1 (da)
NO (1) NO312161B1 (da)
NZ (1) NZ333159A (da)
PE (1) PE135299A1 (da)
PL (1) PL330062A1 (da)
PT (1) PT921125E (da)
SG (1) SG71173A1 (da)
TR (1) TR199802520A2 (da)
TW (1) TW408123B (da)
YU (1) YU55198A (da)
ZA (1) ZA9811128B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237047T3 (es) * 1998-10-23 2005-07-16 Pfizer Inc. Compuestos de 1,3,8-triazaespiro(4,5)decanona como agonistas del receptor orl1.
DE60033071T2 (de) * 1999-12-06 2007-08-23 Euro-Celtique S.A. Triazospiroverbindungen mit nociceptin-rezeptoraffinität
CA2454785C (en) * 2001-07-23 2010-09-07 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiropiperidine derivatives
PT1491212E (pt) * 2002-03-29 2012-11-16 Mitsubishi Tanabe Pharma Corp Medicamento para distúrbios de sono
EA009369B1 (ru) * 2002-09-09 2007-12-28 Янссен Фармацевтика, Н.В. Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором
AU2003299791A1 (en) * 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
NZ544282A (en) * 2003-05-23 2009-07-31 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
CN101146801A (zh) * 2005-03-22 2008-03-19 霍夫曼-拉罗奇有限公司 新型的dpp-iv抑制剂的盐和多晶型物
JP2009541342A (ja) * 2006-06-20 2009-11-26 ワイス Kv1.5カリウムチャネル阻害剤
EA200970517A1 (ru) * 2006-11-28 2009-12-30 Янссен Фармацевтика Н.В. Соли 3-(3-амино-2-(r)-гидроксипропил)-1-(4-фторфенил)-8-(8-метилнафталин-1-илметил)-1,3,8-триазаспиро[4,5]декан-4-она
CA2679530C (en) * 2007-03-01 2012-09-25 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
MX2009011006A (es) * 2007-04-09 2009-11-02 Janssen Pharmaceutica Nv Derivados de 1,3,8-trisustituido-1,3,8-triaza-espiro[4.5]decano-4- ona como ligandos del receptor de orl-1 para el tratamiento de ansiedad y depresion.
PA8801401A1 (es) * 2007-10-25 2009-05-15 Janssen Pharmaceutica Nv Arilindenopirimidinas y su uso como adenosina a2a
TW201016675A (en) * 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
US20100076003A1 (en) * 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
WO2010037081A1 (en) * 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
CN102459278A (zh) 2009-06-16 2012-05-16 默沙东公司 取代的-1,3,8-三氮杂螺[4.5]癸烷-2,4-二酮
CN107849044B (zh) * 2015-07-03 2021-06-25 豪夫迈·罗氏有限公司 作为ddr1抑制剂的三氮杂-螺癸酮类化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155669A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3155670A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3161644A (en) * 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3238216A (en) * 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
JPS5212171A (en) * 1975-07-17 1977-01-29 Yoshitomi Pharmaceut Ind Ltd Process for preparation of cyclohexane derivatives
JPS51100084A (da) * 1975-02-28 1976-09-03 Yoshitomi Pharmaceutical
GB1486546A (en) * 1975-02-28 1977-09-21 Yoshitomo Pharma Ind Ltd 4,4-diphenyl-cyclohexylpiperidine compounds and analogues thereof
JPS5934713B2 (ja) * 1976-01-05 1984-08-24 ウェルファイド株式会社 脂環式誘導体
US4076821A (en) * 1976-02-27 1978-02-28 Yoshitomi Pharmaceutical Industries, Ltd. 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
MA19091A1 (fr) * 1980-03-10 1981-10-01 Janssen Pharmaceutica Nv Nouveaux derives de i-(4-aryl-cyclohexyl)piperidine .
GR73633B (da) * 1980-03-10 1984-03-26 Janssen Pharmaceutica Nv
EP0114787B1 (de) * 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
JPS6012357B2 (ja) * 1984-01-23 1985-04-01 吉富製薬株式会社 脂環式誘導体
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives

Also Published As

Publication number Publication date
NO985684L (no) 1999-06-07
TR199802520A3 (tr) 1999-06-21
ID21413A (id) 1999-06-10
KR19990062800A (ko) 1999-07-26
ZA9811128B (en) 1999-06-07
NZ333159A (en) 2000-06-23
YU55198A (sh) 2001-12-26
US6043366A (en) 2000-03-28
BR9805297A (pt) 2000-02-01
AR016428A1 (es) 2001-07-04
HU9802807D0 (en) 1999-02-01
DK0921125T3 (da) 2002-05-13
ES2170446T3 (es) 2002-08-01
MA26573A1 (fr) 2004-12-20
PL330062A1 (en) 1999-06-07
PT921125E (pt) 2002-06-28
CN1222521A (zh) 1999-07-14
TR199802520A2 (xx) 1999-06-21
DE69803653T2 (de) 2002-08-29
BR9805297B1 (pt) 2010-07-13
AU744338B2 (en) 2002-02-21
CN1118467C (zh) 2003-08-20
IL127399A0 (en) 1999-10-28
DE69803653D1 (de) 2002-03-14
NO985684D0 (no) 1998-12-04
CZ399698A3 (cs) 1999-06-16
HUP9802807A3 (en) 2000-01-28
CO4990965A1 (es) 2000-12-26
JPH11228575A (ja) 1999-08-24
TW408123B (en) 2000-10-11
HRP980613A2 (en) 1999-08-31
CA2255171C (en) 2009-09-29
CA2255171A1 (en) 1999-06-05
PE135299A1 (es) 2000-01-18
ATE212635T1 (de) 2002-02-15
JP3366868B2 (ja) 2003-01-14
AU9608798A (en) 1999-06-24
HUP9802807A2 (hu) 1999-08-30
NO312161B1 (no) 2002-04-02

Similar Documents

Publication Publication Date Title
EG24081A (en) 4-Substituted-9-deoxo-9a-aza-9a-homerythromycin derivatives
HRP970454B1 (en) Substituted 6,5-hetero-bicyclic derivatives
ZA977652B (en) Substituted 6,6-hetero-bicyclic derivatives
ZA98570B (en) 8-substituted-1,3,8-triaza-spiro[4,5]decan-4-on derivatives
HUP0003642A3 (en) N-alkanoylphenylalanine derivatives
GB9702194D0 (en) Sulphonide derivatives
HU9801168D0 (en) Triazinylaminostilbene derivatives
SG71173A1 (en) 1,3,8,-triaza-spiro[4,5]decan-4-on derivatives
ZA987688B (en) 6,9-bridged erythromycin derivatives
IL134996A0 (en) 6,11-bridged erythromycin derivatives
IL126624A0 (en) 3-descladinose-2, 3-anhydroerythromycin derivatives
IL132982A0 (en) Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives
IL136500A0 (en) 1,4-diazacycloheptane derivatives
GB9715821D0 (en) Amidino-camptothecin derivatives
GB2321457B (en) 5-Aroylnaphthalene derivatives
GB9725541D0 (en) Amino-benzothiazole derivatives
GB9701628D0 (en) Imino-aza-anthracyclinone derivatives
SG70589A1 (en) 1, 25-Dihydroxy-16, 22, 23-trisdehydro-cholecalciferol derivatives
ZA983116B (en) Arylsecocholadiene derivatives
IL131159A0 (en) 4-Aminoethoxyindazole derivatives
GB9706753D0 (en) Aralkoxy-morphinan derivatives
SI1005445T1 (en) N-alkanoylphenylalanine derivatives
IL132162A0 (en) 2, 3-Epoxypropionamide derivatives
IL132162A (en) 2,3-epoxypropionamide derivatives
ZA989848B (en) 6,11-bridged erythromycin derivatives